Compare
Corcept Therapeutics Inc vs Emergent BioSolutions Inc. vs Collegium Pharmaceutical, Inc vs Pacira BioSciences, Inc.
| Latest fiscal year | Corcept Therapeutics Inc CORT | Emergent BioSolutions Inc. EBS | Collegium Pharmaceutical, Inc COLL | Pacira BioSciences, Inc. PCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $761.41M | $742.90M | $780.57M | $726.41M |
| Revenue growth (YoY) | +12.8% | -28.8% | +23.6% | +3.6% |
| Gross margin | n/a | 56.1% (computed) | 59.3% | 79.4% (computed) |
| Operating margin | 5.9% | 13.5% | 23.0% | 2.6% |
| Net margin | 13.1% | 7.1% | 8.1% | 1.0% |
| Net income | $99.65M | $52.60M | $62.87M | $7.03M |
| EPS (Diluted) | $0.82 | $0.93 | $1.73 | $0.16 |
| Operating cash flow | $142.00M | $170.60M | $329.32M | $151.99M |
| Free cash flow | $141.78M | $156.80M | $327.58M | $136.66M |
| Cash & equivalents | $120.50M | $205.40M | $231.25M | $158.54M |
| Total assets | $836.65M | $1.32B | $1.66B | $1.26B |
| Total liabilities | $188.85M | $796.00M | $1.36B | $571.81M |
| Shareholders' equity | $647.80M | $522.60M | $301.68M | $693.11M |
| Return on year-end equity | 15.4% | 10.1% | 20.8% | 1.0% |
| Shares outstanding | 105.97M | 52.10M | 31.71M | 41.12M |
Revenue, most recent five fiscal years
| Fiscal year | Corcept Therapeutics Inc | Emergent BioSolutions Inc. | Collegium Pharmaceutical, Inc | Pacira BioSciences, Inc. |
|---|---|---|---|---|
| Latest | $761.41M Ended 2025-12-31 | $742.90M Ended 2025-12-31 | $780.57M Ended 2025-12-31 | $726.41M Ended 2025-12-31 |
| 1 year earlier | $675.04M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $631.45M Ended 2024-12-31 | $700.97M Ended 2024-12-31 |
| 2 years earlier | $482.38M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $566.77M Ended 2023-12-31 | $674.98M Ended 2023-12-31 |
| 3 years earlier | $401.86M Ended 2022-12-31 | $1.12B Ended 2022-12-31 | $463.93M Ended 2022-12-31 | $666.82M Ended 2022-12-31 |
| 4 years earlier | $365.98M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $276.87M Ended 2021-12-31 | $541.53M Ended 2021-12-31 |